Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 19/20 | 0.65 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.52 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.52 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.52 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.52 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.52 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.52 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7801092 | 0.90 | TACR1 (0.64) | TACR1 | |
| Hydrochloric Acid SCHEMBL7790312 | 0.84 | TACR1 (0.72) | TACR1 | |
| SCHEMBL7790406 | 0.82 | TACR1 (0.70) | TACR1 | |
| SCHEMBL7796759 | 0.79 | TACR1 (0.81) | TACR1 | |
| SCHEMBL7573137 | 0.79 | TACR1 (1.00) | TACR1 | |
| SCHEMBL7789923 | 0.75 | TACR1 (0.90) | TACR1 | |
| SCHEMBL7796982 | 0.74 | TACR1 (0.63) | TACR1 | |
| SCHEMBL7801067 | 0.73 | TACR1 (0.67) | TACR1 | |
| SCHEMBL7797104 | 0.73 | TACR1 (0.67) | TACR1 | |
| SCHEMBL7797099 | 0.73 | TACR1 (0.67) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010039286-A1 | 2-aryl indole derivatives and their use as therapeutic agents | DINNELL KEVIN (GB) | 2001-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039286-A1 | 2-aryl indole derivatives and their use as therapeutic agents | IDO1, IDO2, CNR2 | TACR1 1285/4885GRIN2D 158/4885GRIN3B 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.